Haemonetics Corp. (NYSE:HAE) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
Haemonetics Corp. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 20% to $0.48 in the quarter versus EPS of $0.40 in the year-earlier quarter.
Revenue: Rose 33.87% to $249.9 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: Haemonetics Corp. reported adjusted EPS income of $0.48 per share. By that measure, the company beat the mean analyst estimate of $0.46. It beat the average revenue estimate of $249.33 million.
Quoting Management: Brian Concannon, Haemonetics’ President and CEO, commented: “Continued growth in our three product categories – commercial plasma, blood centers, and hospitals – was the highlight of our fourth quarter and fiscal 2013. I’m particularly pleased that such growth came while integrating the largest acquisition in our history without interruption to our business. Customers are increasingly recognizing the value of our Blood Management Solutions offering.”
Key Stats (on next page)…
Revenue increased 1.01% from $247.4 million in the previous quarter. EPS decreased 4% from $0.50 in the previous quarter.
Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.43 and has not changed. For the current year, the average estimate is a profit of $1.69, which is the same with that ninety days ago.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)